Your browser doesn't support javascript.
loading
Comparison of HIV prevalence, incidence, and viral load suppression in Zambia population-based HIV impact assessments from 2016 and 2021.
Mulenga, Lloyd B; Hines, Jonas Z; Stafford, Kristen A; Dzekedzeke, Kumbutso; Sivile, Suilanji; Lindsay, Brianna; Chola, Mumbi; Ussery, Faith; Patel, Hetal K; Abimiku, Alash'le; Birhanu, Sehin; Minchella, Peter A; Stevens, Thomas; Hanunka, Brave; Chisenga, Tina; Shibemba, Aaron; Fwoloshi, Sombo; Siame, Mwiche; Mutukwa, John; Chirwa, Lameck; Siwingwa, Mpanji; Mulundu, Gina; Agbakwuru, Chinedu; Mapondera, Prichard; Detorio, Mervi; Agolory, Simon G; Monze, Mwaka; Bronson, Megan; Charurat, Man E.
  • Mulenga LB; Ministry of Health.
  • Hines JZ; University Teaching Hospital.
  • Stafford KA; University of Zambia, School of Medicine.
  • Dzekedzeke K; U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
  • Sivile S; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Lindsay B; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation-an affiliate of the University of Maryland, Baltimore, Lusaka, Zambia.
  • Chola M; Ministry of Health.
  • Ussery F; University Teaching Hospital.
  • Patel HK; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Abimiku A; Center for International Health, Education, and Biosecurity, Maryland Global Initiatives Corporation-an affiliate of the University of Maryland, Baltimore, Lusaka, Zambia.
  • Birhanu S; U.S. Centers for Disease Control and Prevention, Atlanta, USA.
  • Minchella PA; U.S. Centers for Disease Control and Prevention, Atlanta, USA.
  • Stevens T; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Hanunka B; U.S. Centers for Disease Control and Prevention, Atlanta, USA.
  • Chisenga T; U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
  • Shibemba A; U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
  • Fwoloshi S; U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
  • Siame M; Ministry of Health.
  • Mutukwa J; University Teaching Hospital.
  • Chirwa L; Ministry of Health.
  • Siwingwa M; University Teaching Hospital.
  • Mulundu G; Ministry of Health.
  • Agbakwuru C; Ministry of Health.
  • Mapondera P; University Teaching Hospital.
  • Detorio M; University Teaching Hospital.
  • Agolory SG; University of Zambia, School of Medicine.
  • Monze M; University Teaching Hospital.
  • Bronson M; University of Zambia, School of Medicine.
  • Charurat ME; Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
AIDS ; 38(6): 895-905, 2024 05 01.
Article en En | MEDLINE | ID: mdl-38227572
ABSTRACT

BACKGROUND:

The Zambian government has implemented a public health response to control the HIV epidemic in the country. Zambia conducted a population-based HIV impact assessment (ZAMPHIA) survey in 2021 to assess the status of the HIV epidemic to guide its public health programs.

METHODS:

ZAMPHIA 2021 was a cross-sectional two-stage cluster sample household survey among persons aged ≥15 years conducted in Zambia across all 10 provinces. Consenting participants were administered a standardized questionnaire and whole blood was tested for HIV according to national guidelines. HIV-1 viral load (VL), recent HIV infection, and antiretroviral medications were tested for in HIV-seropositive samples. Viral load suppression (VLS) was defined as <1000 copies/ml. ZAMPHIA 2021 results were compared to ZAMPHIA 2016 for persons aged 15-59 years (i.e., the overlapping age ranges). All estimates were weighted to account for nonresponse and survey design.

RESULTS:

During ZAMPHIA 2021, of 25 483 eligible persons aged ≥15 years, 18 804 (73.8%) were interviewed and tested for HIV. HIV prevalence was 11.0% and VLS prevalence was 86.2% overall, but was <80% among people living with HIV aged 15-24 years and in certain provinces. Among persons aged 15-59 years, from 2016 to 2021, HIV incidence declined from 0.6% to 0.3% ( P -value 0.07) and VLS prevalence increased from 59.2% to 85.7% ( P -value <0.01).

DISCUSSION:

Zambia has made substantial progress toward controlling the HIV epidemic from 2016 to 2021. Continued implementation of a test-and-treat strategy, with attention to groups with lower VLS in the ZAMPHIA 2021, could support reductions in HIV incidence and improve overall VLS in Zambia.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH Tipo de estudio: Incidence_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Humans País como asunto: Africa Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH Tipo de estudio: Incidence_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Humans País como asunto: Africa Idioma: En Año: 2024 Tipo del documento: Article